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Association between post-
transplant uric acid level and renal 
allograft fibrosis: Analysis using 
Banff pathologic scores from renal 
biopsies
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Myoung Soo Kim1,4,5, Hyeon Joo Jeong3,5 & Yu Seun Kim1,4,5
Several experimental studies implicate uric acid in renal injury and fibrosis. The objective of this 
study was to examine the association between uric acid level and allograft fibrosis after kidney 
transplantation. 241 adult patients who underwent kidney transplantation between 2003 and 2014 
were divided into three groups according to the sex specific tertiles of mean uric acid level within the 
first post-transplant year. The renal biopsies performed during 1 to 5 post-transplant year were analyzed 
to compare the degree of interstitial fibrosis and tubular atrophy (IF/TA). Mean interval between kidney 
transplantation and biopsy was similar between groups (23.7 ± 15.3 vs. 30.0 ± 18.6 vs. 27.5 ± 18.5 
months, P = 0.072). The higher tertile uric acid level was, the more advanced grade of IF/TA was shown 
(P = 0.001). Multivariate analysis identified uric acid tertile was independent risk factor for severe IF/TA 
(odds ratio [95% confidence interval] was 3.16 [1.13–8.82] for tertile 2 and 3.70 [1.25–10.93] for tertile 
3, versus tertile 1, respectively). Other independent factors were estimated glomerular filtration rate at 
1year post-transplant (0.80 [CI 0.65–0.98]) and biopsy-proven rejection (2.34 [1.05–5.21]). Graft survival 
over 10 years was significantly lower in tertile 3 (P = 0.041). The results showed that higher uric acid 
level after kidney transplantation was associated with more severe IF/TA.
Outcomes after kidney transplantation (KT) have improved over the years, but the proportion of long-term graft 
failures remains high1,2. Hyperuricemia has been reported as one of the modifiable factors predictive of long-term 
allograft outcomes3–8, although several studies have failed to identify uric acid as an independent risk factor for 
graft loss9–11. These conflicting findings are difficult to reconcile because uric acid is mainly excreted via the 
kidney, so graft function will affect uric acid levels12, and most previous studies focused on estimated glomerular 
filtration rate (eGFR) or loss of graft as an endpoint.
Reported mechanisms for renal injury from hyperuricemia include inhibition of endothelial nitric oxide13 
and activation of the renin angiotensin system14, inducing vasoconstriction15, as well as vascular smooth muscle 
cell proliferation16. These changes lead to progressive renal fibrosis17,18, which is a common histologic finding of 
failing grafts19. In the Banff criteria, allograft fibrosis is defined as interstitial fibrosis and tubular atrophy (IF/TA) 
and graded according to the extent of the affected area20. IF/TA is associated with progression of graft dysfunction 
and graft failure, regardless of the underlying pathologic diagnosis21–23. Various causes of IF/TA are well described 
in literature, including rejection, hypertension, calcineurin inhibitor (CNI) toxicity, infections, and other donor 
or transplant factors24–26.
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Despite the aforementioned experimental evidence, no study has heretofore investigated the pathologic 
changes occurring with hyperuricemia after KT, and the association between uric acid and allograft fibrosis has 
not yet been established in the clinical setting. In this study, our aim was to examine the association between uric 
acid level and allograft fibrosis after kidney transplantation.
Results
Baseline characteristics. Each group of the sex specific uric acid tertile included 80 (tertile 1), 81 (tertile 2) 
and 80 patients (tertil 3). Changes in uric acid level over time during the first post-transplant year were demon-
strated in Fig. 1. Males showed higher mean uric acid values than females for each tertile. Baseline characteristics 
of three groups are demonstrated in Table 1. The intervals between KT and biopsy were similar (23.7 ± 15.3 
vs. 30.0 ± 18.6 vs. 27.5 ± 18.5 months, respectively; P = 0.072), as were the recipient’s sex, donor’s sex, retrans-
plantation, tacrolimus use, blood pressure at 1 year, use of angiotensin converting enzyme inhibitor, use of uric 
acid lowering agent. However, recipient age, the body mass index, the proportions of deceased donors, donor’s 
age, pretransplant diabetes, duration of pretransplant dialysis and delayed graft function were significantly dif-
ferent between groups. The higher tertile of uric acid was, the lower eGFR was at 1 year post-transplant, rep-
resenting an inverse relationship between uric acid levels and allograft function11,27. Biopsy-proven rejection 
was not significantly different but numerically higher in tertile 2 and tertile 3 than tertile 1 (46.3% vs. 56.8% vs. 
65.0%, P = 0.057). Incidences of each diagnosis of biopsy were similar including CNI toxicity and polyoma virus 
nephropathy.
Banff pathologic score. Figure. 2 shows comparisons for average of each pathologic (Banff) score. The ci 
and ct scores were significantly different between the groups (0.4 vs. 0.6 vs. 0.9, P < 0.001 and 0.8 vs. 0.9 vs. 1.2, 
P = 0.002, respectively), and cg score was also different (0.02 vs. 0.08 vs. 0.35, P = 0.001). In the post hoc analysis, 
those 3 chronic scores were significantly higher only in tertile 3 than other two groups (P < 0.001 and 0.010 for ci; 
P = 0.003 and 0.010 for ct; P = 0.001 and 0.009 for cg, vs. tertile 1 and tertile 2, respectively).
Grade of interstitial fibrosis and tubular atrophy. We graded IF/TA from 0 to 3 according to the higher 
value of the ci and ct scores. There was a significant ordered relationship between the grade of IF/TA and uric acid 
level (P = 0.001) (Table 2). Overall severe IF/TA (ci ≥2 or ct ≥2) was 18.3% (n = 44). The higher uric acid tertile 
was, the more frequent severe IF/TA developed (8.8% [n = 7] vs. 19.8% [n = 16] vs. 26.3% [n = 21], P = 0.015). 
Although male patients had higher uric acid level than female, there was no difference in the severity of IF/TA 
between both sexes.
Figure 1. Uric acid changes within the first year after transplantation. The graphs show uric acid changes of 
each tertile group in males (a) and females (b) separately.
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Risk assessment for severe interstitial fibrosis and tubular atrophy. Univariate and multivariate 
analyses showed higher uric acid level was an independent risk factor for severe IF/TA (Table 3). Adjusted odds 
ratio (OR) of uric acid tertile 2 versus tertile 1 was 2.16 (95% confidence interval [CI] 1.13–8.82, P = 0.028) and 
that of tertile 3 versus tertile 1 was 3.70 (95% CI 1.25–10.93). Other independent determinants for severe IF/TA 
were eGFR at 1year post-transplant (per increase of 10 ml/min) (OR 0.8, 95% CI 0.65–0.98) and biopsy-proven 
Figure 2. Comparison of mean values of Banff scores between uric acid tertiles. *P < 0.05 by one way Analysis 
of Variance. ah, arteriolar hyalinosis; cg, glomerular basement membrane double contour; ci, interstitial fibrosis; 
ct, tubular atrophy; cv, vascular fibrous intimal thickening; g, glomerulitis; HighUA, high mean uric acid level; i, 
interstitial inflammation; ptc, peritubular capillaritis; t, tubulitis; v, intimal arteritis.
Variables Tertile 1 (n = 80) Tertile 2 (n = 81) Tertile 3 (n = 80) P
Age (years) 45.0 ± 10.8 40.4 ± 11.4 41.3 ± 12.9 0.031
Sex, males 51 (63.7%) 52 (64.2%) 51 (63.7%) 0.998
Body mass index, (kg/m2) 21.8 ± 2.9 22.9 ± 3.2 22.8 ± 3.3 0.046
Deceased donor 12 (15.0%) 19 (23.5%) 33 (41.3%) 0.001
Donor age (years) 42.6 ± 11.4 43.3 ± 10.9 48.8 ± 9.8 <0.001
Donor sex, males 33 (41.3%) 41 (50.6%) 38 (47.5%) 0.479
Pre-transplant diabetes mellitus 18 (22.5%) 13 (16.0%) 5 (6.3%) 0.015
Duration of pretransplant dialysis (months) 24.9 ± 37.9 29.1 ± 36.4 49.6 ± 53.8 0.001
Retransplantation 4 (5.0%) 5 (6.2%) 8 (10.0%) 0.434
Number of HLA mismatches 2.3 ± 1.2 2.6 ± 1.3 2.3 ± 1.2 0.172
Tacrolimus use 43 (53.8%) 50 (61.7%) 52 (65.0%) 0.327
Delayed graft function 6 (7.5%) 6 (7.4%) 15 (18.8%) 0.032
SBP at 1 year (mm Hg) 125.1 ± 12.5 125.5 ± 12.8 129.2 ± 13.3 0.085
DBP at 1 year (mm Hg) 80.1 ± 10.1 78.7 ± 9.4 81.1 ± 10.3 0.321
Use of ACE inhibitor 47 (58.8%) 48 (59.3%) 44 (55.0%) 0.837
Mean uric acid within the 1st post-transplant year (mg/dL) 4.2 ± 0.6 5.5 ± 0.5 7.1 ± 1.0 <0.001
Use of uric acid lowering agent 4 (5.0%) 5 (6.2%) 7 (8.8%) 0.622
eGFRa at 1 year (mL/min) 65.5 ± 21.6 58.4 ± 19.8 44.3 ± 18.3 <0.001
Interval between KT and biopsy (months) 23.7 ± 15.3 30.0 ± 18.6 27.5 ± 18.5 0.072
Diagnosis of biopsy
  Biopsy-proven rejection 37 (46.3%) 46 (56.8%) 52 (65.0%) 0.057
  Calcineurin inhibitor toxicity 6 (7.5%) 5 (6.2%) 11 (13.8%) 0.205
  Acute tubular injury 6 (7.5%) 5 (6.2%) 6 (7.5%) 0.930
  Polyoma virus nephropathy 5 (6.3%) 4 (4.9%) 9 (11.3%) 0.276
  Diabetic nephropathy 0 (0.0%) 0 (0.0%) 2 (2.5%) 0.131
  IgA nephropathy 5 (6.3%) 5 (6.2%) 4 (5.0%) 0.931
  Focal segmental glomerular sclerosis 1 (1.3%) 7 (8.6%) 3 (3.8%) 0.073
  Immune complex-mediated glomerulonephritis, 
other   than IgA nephropathy 0 (0.0%) 1 (1.2%) 1 (1.3%) 0.606
Table 1. Characteristics of transplant recipients by tertiles of uric acid level. Data are mean ± standard 
deviation or number (%). aCalculated using Chronic Kidney Disease Epidemiology (CKD-EPI) formula. ACE, 
angiotensin converting enzyme; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HLA, 
human leukocyte antigen; KT, kidney transplantation; SBP, systolic blood pressure.
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rejection (OR 2.34, 95% CI 1.05–5.21). When considered as a continuous variable (per increase of 1 mg/dL), uric 
acid was still independent risk factor for severe IF/TA (OR 1.42, 95% CI 1.07–1.88).
Graft survival. The Kaplan-Meier survival curves showed that death censored graft survival over 10 years 
was significantly different between three groups (P = 0.041) (Fig. 3). In the post hoc analysis, only tertile 3 had 
significantly lower survival than tertile 1 (P = 0.036) or tertile 2 (P = 0.041).
Discussion
By comparing Banff pathologic scores from renal biopsies, we demonstrated that higher uric acid was associated 
with more severe fibrosis in transplanted kidneys. Several experimental studies have shown evidence implicating 
uric acid in the progression of fibrosis28. Moreover, a recent study hypothesized molecular mechanism of renal 
injury from soluble uric acid by upregulation of NALP3 inflammasome29 which has been suggested as an endog-
enous pathway of tissue injury in other organs such as lung30 as well as gout31,32. However, it has been debated 
whether hyperuricemia exerts a causal effect on the deterioration of renal allografts and native kidneys with 
chronic disease.
Because serum uric acid and renal function bidirectionally interact with each other, the resultant decline in 
eGFR could mask the effect of uric acid itself, thus necessitating a longitudinal approach examining time-varying 
eGFR and uric acid levels. In a retrospective analysis, Kim et al.10 concluded that uric acid was not an independent 
risk factor for renal allograft loss. However, another large cohort study, using a similar analytical method but a 
longer follow-up period, showed that uric acid was a risk factor7. Additionally, Tsai et al.33 reported that higher 
uric acid levels were independently associated with end-stage renal disease and all-cause mortality in patients 
with chronic kidney disease (CKD) based on the concept of trajectories of uric acid and corresponding eGFRs. 
Even in the Korean population, where the prevalence of gout is low as 0.4%34, there was a report that higher serum 
uric acid was associated with increased risk of CKD35. Demonstration of the relationship between uric acid and 
graft loss or progression of CKD requires long-term follow-up. Therefore, we hypothesized that estimating the 
differences in chronic renal histologic injuries would help distinguish the true effects of uric acid.
Based on analysis of surveillance biopsies, Stegall et al.36 demonstrated that the majority of renal allografts 
functioning over 10 years contained chronic injury. They also alluded to the necessity for intensive management 
of metabolic factors. Another study reported that rejection or the underlying presence of donor-specific antibody 
IF/TA 
grade
All subjects 
(n = 241)
Tertile 1
(n = 80)
Tertile 2
(n = 81)
Tertile 3
(n = 80) aP
0 47 (19.5%) 19 (23.7%) 20 (24.7%) 8 (10.0%) 0.001
1 150 (62.2%) 54 (67.5%) 45 (55.5%) 51 (63.7%)
2 33 (13.7%) 5 (6.3%) 14 (17.3%) 14 (17.5%)
3 11 (4.6%) 2 (2.5%) 2 (2.5%) 7 (8.8%)
Table 2. Difference in the grade of IF/TA between uric acid tertiles. aby Manteal-Haenzel chi square test. IF/TA, 
interstitial fibrosis and tubular atrophy.
Variables
Univariate Multivariatea
OR (95% CI) P OR (95% CI) P
Uric acid tertile
  Tertile 1 Reference Reference
  Tertile 2 2.57 (0.99–6.63) 0.052 2.16 (1.13–8.82) 0.028
  Tertile 3 3.71 (1.48–9.33) 0.005 3.70 (1.25–10.93) 0.018
Age, years 0.96 (0.93–1.01) 0.083
Sex, male 0.55 (0.29–1.07) 0.078
Body mass index 0.85 (0.76–0.96) 0.007 0.79 (220.69–1.30) 0.101
Deceased donor 1.37 (0.67–2.79) 0.383 0.83 (0.31–2.20) 0.702
Donor age, years 0.99 (0.96–1.02) 0.539 0.96 (0.93–1.01) 0.063
Retransplantation 0.96 (0.26–3.48) 0.946
Delayed graft function 2.56 (1.06–6.16) 0.036 1.55 (0.46–5.25) 0.479
SBP at 1year (every 10 mmHg) 1.07 (0.94–1.38) 0.578
Use of ACE inhibitor 0.77 (0.40–1.47) 0.423
Use of uric acid lowering agent 1.54 (0.47–5.03) 0.473
eGFR at 1year (every 10 ml/min) 0.81 (0.69–0.96) 0.014 0.80 (0.65–0.98) 0.036
Biopsy-proven rejection 2.79 (1.34–5.84) 0.006 2.34 (1.05–5.21) 0.037
Table 3. Risk factors associated with severe IF/TA. aMultivariate analysis was performed by logistic regression. 
ACE, angiotensin converting enzyme; CI, confidence interval; eGFR, estimated glomerular filtration rate; IF/
TA, interstitial fibrosis and tubular atrophy; KT, kidney transplantation; OR, Odds ratio; SBP, systolic blood 
pressure.
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(DSA) might be major determinants of fibrosis25. However, treatment benefits after subclinical rejection have so 
far been restricted to low-risk recipients and have not yet been established in cases of long-term graft survival26, 
indicating that immunologic causes are not the only factors deserving attention. From this perspective, uric acid 
could be one of the primary concerns in preventing allograft fibrosis.
Few studies have described the relationship between uric acid and allograft fibrosis. Alkalin et al. reported that 
hyperuricemia was associated with chronic allograft nephropathy (CAN)37, but that terminology is now outdated 
and, more specifically, it includes rejection and nonspecific tubulointerstitial fibrosis. Furthermore, hyperurice-
mia was an independent risk factor for pooled outcomes including death, graft loss, and CAN, but not for CAN 
alone. More recently, Hart et al.38 demonstrated that hyperuricemia was a risk factor for doubling of the interstit-
ium or end– stage renal disease from IF/TA after KT in a post hoc analysis of a prospective study. However, this 
study involved a small study population and the multivariate analysis endpoint was intermixed with graft losses 
from all other causes. Therefore, it was not clear whether hyperuricemia independently increased the risk of IF/
TA. Additionally, neither of those two studies compared pathologic scores or considered the underlying patho-
logic diagnoses. Our results provided more definitive information about the relationship between uric acid level 
and allograft fibrosis by analyzing pathologic scores as endpoints, especially in the presence of known risk factors 
such as corresponding renal function and rejection.
In a Korean population study, they showed early post-transplant hyperuricemia was an independent risk 
factor for allograft loss7. In contrast, we divided KT patients according to sex specific tertiles of serum uric acid 
and showed an ordered relationship between uric acid level and IF/TA; even tertile 1 showed less severe IF/TA 
than tertile 2 of which uric acid level was conventionally normal. This result could provide not only a pathologic 
evidence to support previous studies about uric acid and allograft outcome4,5,7,8 but also an inspiration for the 
future study on lowering uric acid below the normal level to reduce allograft fibrosis.
In a recent review, Vanhove et al. summarized several therapeutic approaches to reducing the progression of 
allograft fibrosis after KT, such as CNI-sparing immunosuppression, reduction of renin-angiotensin-aldosterone 
system activation, appropriate management of subclinical rejection, and direct intervention for fibrogenic mole-
cules26. No interventional study has examined the effects of hyperuricemia treatment on renal fibrosis, but many 
studies have examined the effects of uric acid-lowering agents on eGFR decline in patients with CKD39. These 
include a well-designed randomized controlled trial using febuxostat, which is a newly developed xanthine oxi-
dase inhibitor40. In the transplantation field, only a few retrospective, small-volume studies have evaluated the 
effects of lowering uric acid levels on renal allograft outcome41–43. The extent to which hyperuricemia contributes 
to fibrogenesis of an allograft has not been fully established, especially in the presence of immunologic challenges; 
however, our study shows that lowering uric acid levels could be an antifibrotic option.
Our study has limitations. As reported in a recent large cohort study, circulating DSA is one of the main 
contributors to allograft fibrosis25, but it was not assessed in this study because laboratory detection of DSA 
has been available in our institution since only 2011. Also, because renal biopsies are not standard parts of the 
post-transplant protocols in our institution, the biopsies included in this study were performed only when 
deemed indicated by the clinical care team. So, we could not show the changes over time in pathologic scores 
representing graft fibrosis. A study with routine serial biopsies is necessary to provide more information about 
the effect of higher uric acid on fibrosis progression.
Despite these limitations, our study demonstrated that higher uric acid level was an independent risk factor 
for severe IF/TA after kidney transplantation, even in the presence of corresponding renal allograft function 
and rejection. The results would be not only a good help for the clinical decision about lowering serum uric acid 
after kidney transplantation but also inspiration for the future research on the allograft fibrosis and long-term 
outcome.
Figure 3. Kaplan-Meier survival estimates for death censored graft survival over 10 years.
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Methods
Materials. We conducted a retrospective analysis of prospectively collected data from 296 patients who 
underwent KT from January 2003 to December 2014 and received renal biopsy during 1 to 5 post-transplant 
year. The exclusion criteria were as follows: (1) age <18 years at the time of KT, (2) multi-organ transplantation, 
(3) ABO-incompatible KTs, (4) crossmatch-positive KTs, and (5) insufficient uric acid data (Fig. 4). Finally, 241 
patients were analyzed in this study. The biopsies were performed in our study population solely when clinically 
indicated, such as for increases in serum creatinine or increases in proteinuria. Biopsies performed at the time of 
surgery were not considered.
Data collection. We obtained serum uric acid levels at 1, 3, 6, 9, and 12 month post-transplant. Patients were 
divided into three groups according to the sex specific tertiles of their mean uric acid level within the first year. 
Characteristics of the recipients and donors were also collected from the database.
Pathologic review. All biopsies performed between 1 and 5 year post-transplant were examined by expe-
rienced renal pathologists (HJJ, BJL) and scored for glomerulitis (g), interstitial inflammation (i), tubulitis (t), 
intimal arteritis (v), peritubular capillaritis (ptc), glomerular basement membrane double contour (cg), interstitial 
fibrosis (ci), tubular atrophy (ct), vascular fibrous intimal thickening (cv), and arteriolar hyalinosis (ah)44. In case 
of multiple results of biopsy during study period, highest value of each score were recorded. Interstitial fibrosis 
and tubular atrophy are known to consistently occur together45, so IF/TA was graded according to the higher of 
the ci score or ct score.
We reviewed the pathology reports diagnosed by criteria before the 2007 Banff meeting report46 so that 
rejection diagnosis could be determined using the 2007 diagnostic criteria. Other pathologic diagnoses were 
confirmed in each biopsy, including CNI toxicity, acute tubular injury, polyomavirus nephropathy, diabetic 
nephropathy, IgA nephropathy, focal segmental glomerulosclerosis, and immune complex-mediated glomeru-
lonephritis other than IgA nephropathy.
Study endpoints. Our primary endpoint was incidence of severe IF/TA (ci ≥ 2 or ct ≥ 2)25. We also investi-
gated the difference in death censored graft survival between groups.
Statistical analysis. Data are shown as mean ± standard deviation for continuous variables and number 
(frequency) for categorical variables. The one-way Analysis of Variance and chi square test were used when appro-
priate. To examine ordered-relationship between uric acid tertile and degree of IF/TA, the Mantel-Haenszel chi 
square test was performed. Logistic regression was utilized in the univariate and multivariate analyses to deter-
mine whether uric acids levels independently affected allograft fibrosis. Considering the sizes of the study popu-
lations, only covariates with a P value < 0.05 in the univariate analysis and known risk factors of allograft fibrosis 
in the literature were entered into the multivariate analysis. Univariate and multivariate results were reported as 
odds ratios (ORs) with 95% confidence intervals (CIs). Kaplan-Meier survival curves were compared using the 
log rank test. All analyses were performed using SPSS software (version 23.0; SPSS, Inc., Chicago, IL, USA) and P 
values < 0.05 were considered statistically significant.
Ethic statement. The study was conducted according to the principles of the Declaration of Helsinki and 
approved by the independent Institutional Review Board of Yonsei University College of Medicine (IRB No.: 
4-2017-1154).
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